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Circulating microRNAs, present either in the cellular component, peripheral blood
mononuclear cells (PBMC), or in cell-free plasma, have emerged as biomarkers for
age-dependent systemic, disease-associated changes in many organs. Previously, we
have shown that microRNA (miR)-34a is increased in circulating PBMC of Alzheimer’s
disease (AD) patients. In the present study, we show that this microRNA’s sister, miR-34c,
exhibits even greater increase in both cellular and plasma components of AD circulating
blood samples, compared to normal age-matched controls. Statistical analysis shows the
accuracy of levels of miR-34c assayed by receiver operating characteristic (ROC) analysis:
the area under the curve is 0.99 (p < 0.0001) and the 95% confidence level extends
from 0.97 to 1. Pearson correlation between miR-34c levels and mild and moderate AD,
as defined by the mini-mental state examination (MMSE), shows an r -value of −0.7,
suggesting a relatively strong inverse relationship between the two parameters. These
data show that plasma levels of microRNA 34c are much more prominent in AD than
those of its sister, miR-34a, or than its own level in PBMC. Transfection studies show that
miR-34c, as does its sister miR-34a, represses the expression of several selected genes
involved in cell survival and oxidative defense pathways, such as Bcl2, SIRT1, and others,
in cultured cells. Taken together, our results indicate that increased levels of miR-34c in
both PBMC and plasma may reflect changes in circulating blood samples in AD patients,
compared to age-matched normal controls.
Keywords: peripheral blood mononuclear cells (PBMC), plasma microRNA, miR-34a, miR-34c
INTRODUCTION
Recently, microRNAs found in circulating blood, especially
in cell-free plasma, have been noted functionally for inter-
cellular and/or inter-organ communication. Circulating plasma
microRNAs seem to be largely released from the cellu-
lar compartment, i.e., peripheral blood mononuclear cells
(PBMC), either associated with specific protein or lipid
molecules, or released in vesicles known as exosomes, with
some portion derived from the cell debris of apoptotic bod-
ies (Smalheiser, 2007; De Smaelea et al., 2010; Etheridge
et al., 2011). Not surprisingly, differentially expressed plasma
microRNAs have been noted as powerful biomarkers for sev-
eral central nervous system disorders, from bipolar disorder
to schizophrenia, Huntington’s disease and Alzheimer’s dis-
ease (AD) (Gaughwin et al., 2011; Rong et al., 2011; Suarez-
Gomez et al., 2011; Geekiyanage et al., 2012; Sheinerman
et al., 2012; Shi et al., 2012). Our own work has shown
Abbreviations: miR or miRNA, microRNA; AD, Alzheimer’s disease; NEC, nor-
mal elderly control; MMSE, Mini-Mental State Examination; MMSE score (4–9),
severe group; MMSE score (10–20), moderate group; MMSE score (21–24), mild
group; Bcl2, B-cell lymphoma 2; SIRT1, sirtuin1; Psen1, presenilin-1.
that lead microRNAs are differentially regulated in PBMC of
AD patients compared with age-matched controls (Schipper
et al., 2007; Maes et al., 2010). Therefore, unique microRNAs
offer another aspect, in addition to specific transcriptome and
serum protein profiling: blood biomarker discovery, for instance
for AD.
Among many microRNAs, the miR-34 family, composed of
three members, miR-34a, -34b, and -34c, is relatively well-
understood. MicroRNA-34b, a plasma biomarker for Huntington
disease (Gaughwin et al., 2011), and its sister, miR-34c, are
linked as a bi-cistronic transcriptional unit (Liang et al.,
2009); together with the other sister, miR-34a, they par-
ticipate functionally in at least two signaling pathways: (1)
Bcl2 for cell survival/apoptosis; and (2) SIRT1 deacetylase
for p53 or neuroprotection signaling. SIRT1, p53, and miR-
34a are involved in a positive feedback loop for miR-34a
expression: acetylated p53 binds the promoter to activate this
microRNA’s transcription (He et al., 2007; Yamakuchi et al.,
2008). Increased miR-34a suppresses SIRT1 expression, thereby
diminishing its deacetylation of p53, leading to an increase
in acetylated p53 transcriptional activity, resulting in the
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continued up-regulation of this microRNA (Yamakuchi et al.,
2008).
Many reports, including our own work in aged mice, observe
parallel changes during aging between differentially regulated cir-
culating microRNAs and changes in the central nervous system
(Li et al., 2011a). During aging, accumulating oxidative stress-
activated p53 may tilt the balance toward age-dependent increase
of miR-34a, observed in the brains of old rats and mice (Li et al.,
2011b,c); and a reduction in age-dependent increase in miR-34a
in brain has been observed in calorie-restricted mice (Khanna
et al., 2011). In animal models of AD, increased miR-34a levels
are observed in brains of mouse models bearing both the APPswe
and presenilin transgenes (Wang et al., 2009). MicroRNA 34-c,
a sister of miR-34a, is also observed in the hippocampal region
of AD animal models to be functionally connected to cognitive
decline, because inhibition of this microRNA rescues memory
impairment in AD transgenic mice, with corresponding regained
SIRT1 levels (Zovoilis et al., 2011). These results suggest that
increased expression of miR-34a and -34c may repress SIRT1 and
Bcl2 expression, one of the many underlying causes for dysregu-
lation of oxidative defense and neuronal cell survival in the brain
of AD transgenic animals.
The main objective of this study is to test the hypothesis that
unique microRNA changes in AD patients, specifically those of
the microRNA-34 family, can be identified in circulating blood
samples in both the cellular component, PBMC, and cell-free
plasma. To test this hypothesis, we have expanded beyond our
previous observation of increased miR-34a in PBMC of AD
patients (Schipper et al., 2007) to include also miR-34c in our
study of specimens of both blood components. Here, we report
that miR-34c in circulating plasma and PBMC indeed exhibits
increased levels of expression in AD patients, compared with
age-matched normal elderly controls (NEC). Transfection study
shows that miR-34c, similar to reported findings for miR-34a,
functionally represses Bcl2, SIRT1, and other proteins, all key
genes whose decreases are functionally associated with weakened
oxidative defense and cell survival.
MATERIALS AND METHODS
SUBJECTS AND CLINICAL EVALUATION
Informed consent was obtained from all participants, follow-
ing the Institutional Review Board protocol approved by the
Sir Mortimer B. Davis Jewish General Hospital (JGH) Research
Ethics Committee. Blood samples were obtained from subjects
at the Memory Clinic at the JGH, from 110 AD patients (age:
56–90) and 123 NEC (age: 61–90) without cognitive impair-
ment. NEC were recruited by newspaper advertisements and
public lectures, scored less than 4 on the Subjective Memory
Scale of Schmand (Schmand et al., 1996), lacked other medical
or neurological illnesses, and scored within 1 standard devia-
tion (SD) of age and education means on memory screening
tests. These consist of scores of 26 or more on the Montreal
Cognitive Assessment (MoCA) (Nasreddine et al., 2005), a Mini-
Mental State Examination (MMSE) scoring 25 or above (Folstein
et al., 1975), and normal range scores on the delayed paragraph
recall component of the Logical Memory Test of the WAIS-
R (Wechsler, 2008). Patients with sporadic late onset AD were
screened and assessed at the JGH McGill University Memory
Clinic in Montréal; the diagnosis was made according to stan-
dard NINCDS-ADRDS criteria (McKhann et al., 1984), and
conformed to the more recent revised criteria for probable AD as
well (McKhann et al., 2011). Severity of dementia was stratified
according to MMSE results: mild (21–24), moderate (10–20), or
severe (4–9).
BLOOD COLLECTION AND ISOLATION AND QUALITY EVALUATION OF
RNA SAMPLES
Approximately 30ml of blood per donor was collected in EDTA
vacutainers, and processed to isolate the plasma and PBMC frac-
tions, using Ficoll-Plaque Plus (GE Healthcare, Piscataway, NJ).
PBMC and plasma samples, stored in RNAlater buffer solution
(Ambion, Austin, TX), were processed for RNA and protein
isolation by Trizol/chloroform and centrifugation, to separate
the upper RNA-containing aqueous phase from the lower pro-
teinaceous phase, for isolation of microRNA from the plasma
specimens, as previously described (Li et al., 2011a). Prior to RNA
isolation, 0.625 ng of synthetic miRNA-39 from Caenorhabditis
elegans (cel-miRNA-39) was added to the Trizol as a spike-in
control for purification efficiency and cDNA synthesis quality val-
idation during qPCR assays, as described below (Kroh et al., 2010)
(Exiqon, #203203). RNA integrity was assessed using a Nanodrop
spectrophotometer (Thermo Fischer Scientific, Barrington, IL)
and Agilent 2100 bioanalyzer (Agilent Technologies, Waldbronn,
Germany).
TAQMANMicroRNA REAL TIME qPCR
Plasma microRNAs were used to generate cDNA using the
Taqman® MicroRNA Reverse Transcription Kit (Applied
Biosystems, Carlsbad, CA), with specific miRNA stem-loop
primers for miR-34a, -34b, -34c, and -16, by MultiScribe Reverse
Transcriptase; the reactions were carried out in a GeneAmp PCR
System 9700 (Applied Biosystems). These cDNA samples were
processed to assess mature miRNA levels by real time polymerase
chain reactions (qPCR) using the Taqman®Universal PCRMaster
Mix kit (Applied Biosystems). The qPCR was conducted in a 7500
real time PCR system (Applied Biosystems) under the following
conditions: 95◦C 10min, 60 cycles of 95◦C 15 s, and 60◦C 1min.
The levels of mature cel-miR-39 mRNA were measured using
individual TaqMan microRNA Assays (Applied Biosystems)
according to the manufacturer’s instructions (Exiqon, #203203);
cel-miR-39 was used to normalize miRNA levels. A mean Ct was
calculated for C. elegans miRNA for each sample, followed by
calculating the median of all mean C. elegans synthetic miRNA
Cts, taking all samples into consideration. Then a normalization
factor was calculated for each sample by subtracting the mean C.
elegans synthetic miRNA Ct of the sample of interest from the
median value calculated earlier. This normalization factor was
then integrated into the calculation of the raw Ct value obtained
for each sample, which was further normalized by reference to Ct
values for miR-16.
WESTERN BLOT ANALYSES
Western blot analyses were performed as previously described
(Bates et al., 2010; Li et al., 2011c), using an actin band
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for transfection cell lysates, to check equal loading across
all lanes (Pendyala et al., 2010). The antibodies used were
mouse anti-Bcl2 (1:1000, 692, Abcam Inc., Cambridge, MA),
rabbit anti-Psen1 (1:500, 71181;Abcam), rabbit anti-Onecut2
(1:500, 28466;Abcam), rabbit anti-SIRT1 (1:500, 110304;Abcam),
and rabbit anti-β-actin (1:1000, 8226;Abcam). Goat anti-mouse
(31403, Thermo Fischer Scientific, Barrington, IL) was used for
Bcl2 (1:2000), and goat anti-rabbit (31460, Thermo Scientific)
for β-actin, SIRT1, Psen1, and Onecut2 (1:1000) as secondary
antibodies. Intensities of antibody reactive bands were detected
by Enhanced Chemiluminescence (ECL), (Pierce Biotechnology,
Rockford, IL), and quantified by densitometry using ImageJ
software (Public domain, NIH, USA).
CONSTRUCTION OF hsa34a AND hsa34c GFP RECOMBINANTS, AND
FUNCTIONAL TARGET SUPPRESSION STUDY
Micro-34a and -34c were amplified from DNA purified from
human embryonic kidney cells (HEK 293 cell line; ATCC# CRL
1573) with the following primers:
miR-34a forward 5′-tctagaGAG TCC CCT CCG GAT
GCC GTG,
reverse 5′-ggatccCCA CCC ACCG TGG CGC AG, 229 bp;
miR-34c forward 5′-tctagaAGC CCC TCC ATC CAT GTA
ACG GT,
reverse 5′-ggatccAAC ACC CCT CTT CCC CAC GCA, 328 bp.
Amplified PCR products were purified and cloned by the Qiagen
PCR Cloning kit (Qiagen, Valencia, CA), and subcloned into
the pCDH-CMV-MCS-EF1-copGFP vector (System Biosciences,
Mountain View, CA), which was then used for functional assays
by transfecting human embryonic kidney cells (HEK 293), as
previously described (Bates et al., 2010).
STATISTICAL ANALYSES
All statistical analyses were performed using MS Excel 2010, SPSS
17.0 statistical software package (IBM), or SAS version 9.2 (SAS
Institute Inc., Cary, NC). Student’s t-test and one-way analysis
of variance (ANOVA) were performed to determine significant
differences for two-way or more than two groups. For multi-
ple comparisons, Fisher’s Least Significant Difference (LSD) test
was used, following one-way ANOVA, in order to assign sta-
tistical significance, and then the Scheffé test was applied to
reduce Type 1 errors. Levels of miR-34c, miR-34b, and miR-
34a were normalized with regard to miR-16, as recommended
by the manufacturer as well as a previous report of Huntington
disease plasma biomarker discovery (Gaughwin et al., 2011),
as a reference gene, using the comparative Delta Ct method.
The Ct value is the difference between the Ct of the tar-
get microRNA and that of the reference microRNA (Ct = Ct
miR34× − Ct miR16). To include the spike-in results in this
calculation, the Ct values were first normalized against Cel-39
and then against miR-16, according to the equation: normaliz-
ing factor = median (Avg.CtCelall − Avg.CtCelsample); normalized
Ctsample = Ctsample + normalizing factor (Livak and Schmittgen,
2001). Correlation between MMSE scores and expression levels
of miR-34c and miR-34a in AD and NEC patients was calcu-
lated using the Pearson correlation coefficient (r) (Taylor, 1990);
a correlation coefficient value of 0.8 or above indicates strong
correlation, whereas a value around 0.5 is indicative of moderate
correlation.
Receiver-Operating Characteristic (ROC) curves were used to
determine the accuracy of the test differentiating AD from NEC
individuals for miR-34c and miR-34a in age-matched cohorts
(Zweig and Campbell, 1993; Fawcett, 2006). We calculated the
sensitivity, specificity and accuracy as follows;
Sensitivity = TP/(TP + FN) = (Number of true positive
assessments)/(Number of all positive assessments);
Specificity = TN/(TN + FP) = (Number of true negative
assessments)/(Number of all negative assessments)
Accuracy = (TN + TP)/(TN + TP + FN + FP) = (Number
of correct assessments)/(Number of all assessments)
A true positive (TP) is defined as an individual showing concor-
dance between disease presence and a diagnostic test result, while
a true negative (TN) represents disease absence with test result
also negative. Contrary to these scenarios is discordance between
these two categories: i.e., a false positive (FP) is defined as disease
absence in an individual whose diagnostic test is positive, and a
false negative (FN) characterizes disease presence in an individual
whose diagnostic test is negative. All four counts, i.e., TP, TN, FP,
and FN, were calculated with a cut-off point base (Li and Chung,
2013).
RESULTS
SELECTION OF SAMPLES FOR BEST RNA QUALITY, AND CONTROLS
FOR CALCULATION OF miR-34a AND miR-34c LEVELS
From blood samples of 110 AD patients and 123 NEC, only 78
AD and 85 plasma specimens were selected to meet our require-
ments for RNA integrity: a single peak of small RNA in the 4–40
nucleotide (nt) range (Figure 1S). The age range for the AD group
is between 56 and 90, with an average age of 80; the NEC cohort is
between 61 and 90, with an average of 72 (Table 1). Our cohort’s
cognitive ability, assessed by the MMSE, is as reported in the
literature (Sharp and Gatz, 2011), i.e., lower scores are linked
with fewer years of education in AD individuals (Figure 2S). Our
recruitment program for normal control individuals is limited by
the fact that many are in their 60 s. In order to achieve an age-
matched study design, we further selected from the AD and NEC
groups such that the age range of both subcohorts lies between
76–90; the average age for the former is 82, and the latter 80
(Table 1).
To optimize the accuracy of quantitative PCR assays, we used
two control steps: (a) quality control for the cDNA synthesis step
with C. elegans Cel 39 spike-in; and (b) using miR-16 to stan-
dardize baseline level determination. Figures 1A–D shows similar
levels of miR-34a and miR-34c with and without spike-in experi-
ments in both AD and NEC plasma samples. These results suggest
that the protocol established for miR-34a and miR-34c qPCR
assays is stringent, providing optimal quality cDNA synthesis with
minimal putative RT-RNA inhibitions. An additional standard-
ized control is selecting appropriate microRNAs with no changes
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Table 1 | Plasma specimens from the entire cohorts of Alzheimer’s
disease (AD) and normal elderly control (NEC) individuals, selected
after RNA quality control, with age range, average age with standard
deviation (SD), and sample size (N) for acceptable RNA in the entire
cohort and age-matched cohorts.
Original Acceptable RNA Age-matched
N Age range Avg (SD) N Age range Avg (SD) N
AD 110 56–90 80 (6.17) 78 76–90 82 (4.11) 25
NEC 123 61–90 72 (1.31) 85 76–90 80 (3.26) 27
FIGURE 1 | Box plot representation of data from spike-in experiment
with AD and NEC samples, miR-34c, with spike-in (A) and without
spike-in (B) of Cel-39; and miR-34a with spike-in (C) and without
spike-in (D). These figures show that levels of miR-34a and miR-34c are
similar with and without spike-in experiments in both Alzheimer disease
(AD) and normal elderly control (NEC) plasma samples. The Ct values of
miR-16 in AD and NEC samples are represented as box plots in the whole
population (E) and age-matched cohorts (F). These figures indicate that
levels of miR-34a and miR-34c are of the same range in both total and
age-matched cohorts among both AD and NEC plasma samples. Student’s
t-test was used to determine statistical significance; ∗∗P < 0.01.
between AD and control group blood samples. We followed the
manufacturer’s recommendation, as well as reports by Kroh et al.
(2010) and Gaughwin et al. (2011) to use miR-16 as the con-
trol for each individual qPCR assay. However, since miR-16 is an
abundant microRNA associated with red blood cells, even min-
imal hemolysis can cause unreliable qPCR results, as shown by
Müller et al. (2014) in cerebrospinal fluid (CSF) qPCR assays.
In this context, we evaluated miR-16 levels in all samples used
in our study, as shown in Figures 1E,F, and found that in both
total and age-matched cohorts, levels of this microRNA are simi-
lar between the AD and NEC cohorts. Thus, miR-16 levels are not
differentially regulated between AD and NEC plasma samples in
our study, and can serve as a standard.
EXPRESSION LEVELS OF miR-34a AND miR-34c IN PLASMA SAMPLES
OF AD PATIENTS AND NORMAL ELDERLY CONTROLS (NEC)
Our initial study of quantitative reverse transcription PCR
(qPCR) analyses of transcript levels of miR-34a and -34c in
plasma samples of AD and NEC was performed with the entire
cohorts (Table 1). WhenmiR-34c levels were analyzed, NEC indi-
viduals were distributed in a close cluster around the median
levels of the box plots, while AD specimens were distributed
over a wider scatter span, with significantly wider SD range
(Figures 2A,B). Similar wide spreads of AD values while NEC
samples are clustered were also observed with miR-34a levels
(Figures 2C,D). Table 2 shows the wide distribution and high SD
indices for both microRNAs in the AD group. To address the
concern that higher AD microRNA values could be due to the
older age group used, we next selected from our cohorts NEC
individuals age-matched to AD counterparts, as listed in Table 1.
Figures 3A,B shows box plots and distribution of individual
values for miR-34c in the two age-matched subcohorts. Clearly,
the majority of AD plasma specimens in the age-matched con-
trol study exhibit higher miR-34c levels than do normal controls;
Table 3 shows 1/deltaCt values in the 0.20–0.53 range for AD,
and 0.05–0.22 for NEC plasma specimens. When levels of miR-
34a were analyzed, however, the range of distribution is not
differentially expressed between the AD and NEC groups, with
more spread-out distribution for both groups, as well as sig-
nificant overlapping ranges, by both box plot and scatter plots
(Figures 3C,D; Table 3). Levels of miR-34b were evaluated in the
same age-matched subcohorts of the AD and NEC groups in
plasma; the results show no significant difference between the
two groups (Figure 3S, Table 1S). The box plot presentation of
inverted Ct values from AD and NEC groups shows no change,
indicating that the level of miR-34b does not change in the AD
group compared to NEC.
Accuracy in differentiating AD (n = 25) and NEC (n = 27)
individuals by miR-34c levels in plasma specimens was further
tested by ROC curves (Figure 4). The area under the miR-34c
curve is 0.99 (p < 0.0001), essentially 1.0, indicating perfect accu-
racy of the data; 95% confidence interval values fall in the range of
0.97–1.0. The ROC curve shows that miR-34c level is an excellent
test for AD, with 94% accuracy, 92% sensitivity, and 96% speci-
ficity (Table 4). The area under the ROC curve for miR-34a is 0.81
(p = 0.0001), indicating a fairly good test; the 95% confidence
interval lies between 0.69 and 0.93. The sensitivity is 84%, and
specificity is 74% (Figure 4, Table 4). The area under the ROC
curve, sensitivity, specificity and accuracy were calculated for a
cut-off point chosen using the coordinates of ROC curves with
balanced levels of high sensitivity and specificity.
miR-34c LEVELS IN MODERATE AND MILD AD COMPARED WITH
AGE-MATCHED NORMAL ELDERLY CONTROLS
In our age-matched AD cohort, only two patients were evalu-
ated by the MMSE in the severe stage, with scores in the range
4–9. Figures 5A,B show that when these two individuals’ sam-
ples are excluded from our analysis, miR-34c levels in samples
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FIGURE 2 | Transcript levels of miR-34a and miR-34c in plasma
samples of Alzheimer’s disease (AD) patients and normal elderly
controls (NEC). (A) Comparison of plasma levels of miR-34c in the whole
population of AD patients (n = 78) with the NEC cohort (n = 85). (B)
Distributions of individuals’ levels of miR-34c along the box plot. NEC
individuals were distributed in a close cluster around the median levels of
the box plots, whereas AD specimens were distributed over a wider range
with higher standard deviation. (C) Box plot representation of comparison
in plasma levels of miR-34a in the whole population of AD patients (n = 78)
with the NEC cohort (n = 85). (D) Individual miR-34a values along the box
plot are less wide spread in the AD group as compared to those for
miR-34c and a tight cluster for NEC is also observed. The data are plotted
as inverse Ct derived from qPCR analysis. Data points of Mini-Mental
Status Examination (MMSE) score ranges are: severe AD (score 4–9),
moderate AD (score 10–20), mild AD (score 21–24), AD outlier (score
25–29), NEC (score 25–30). Student’s t-test was used to determine
statistical significance; ∗∗P < 0.01.
Table 2 | Plasma microRNA 1/deltaCt level ranges in Alzheimer
disease (AD) patients and normal elderly controls (NEC) with
standard deviation (SD) and median, for miR-34c and miR-34a in the
whole cohorts.
Whole cohort miR-34c miR-34a
Range (SD) Median Range (SD) Median
AD 0.09–0.75 (0.15) 0.21 0.09–0.32 (0.05) 0.15
NEC 0.04–0.24 (0.05) 0.08 0.06–0.17 (0.02) 0.1
from moderate and mild stages, with MMSE scores in 10–20
or 21–24 ranges respectively, remain higher than NEC controls.
Table 5 shows that levels of miR-34c expression are not only dis-
tinct between the moderate and NEC groups, but also between
the mild group and normal controls, with the former in the range
of 0.21–0.38, while the latter shows 0.05–0.22 1/deltaCt values.
Similar separation between mild AD patients and the normal
control group is not observed for levels of miR-34a in this age-
matched cohort study, due to overlapping ranges between these
two groups (Table 5).
We investigated further the relationship between MMSE and
miR-34c levels, by calculating Pearson’s correlation r-value of
miR-34c levels and MMSE scores for moderate and mild AD
and age-matched control cohorts. Figure 6A shows an r-value
FIGURE 3 | Transcript levels of miR-34a and miR-34c in plasma
samples of age-matched cohorts of Alzheimer’s disease (AD) patients
and normal elderly controls (NEC). (A) Plasma level comparison of
miR-34c in the age-matched cohort of AD patients (n = 25) with the NEC
cohort (n = 27). AD plasma samples in the age-matched cohort showed
higher miR-34c levels than controls. (B) Distribution of individuals’ levels of
miR-34c along the box plot; NEC individuals were distributed in a close
cluster around the median of the box plots, while AD patients were
distributed over a wider range with greater standard deviation. (C)
Comparison of plasma levels of miR-34a in age-matched cohorts of AD
patients (n = 25) with the NEC cohort (n = 27). miR-34a levels were
distributed in a range that is not differentially expressed between AD and
NEC groups, with more spread-out distribution for both groups, as well as
significant overlapping ranges, by both box and scatter plots. Distributing
individuals along the box plot, NEC were distributed in a close cluster
around the median levels of the box plots, whereas AD specimens were
distributed over a wider range with higher standard deviation. Data points
represent Mini-Mental Status Examination (MMSE) score as follows, ( )
severe AD (4–9), ( ) moderate AD (10–20), ( ) mild AD (21–24), and ( )
NEC (25–30). (D) Representation of individual miR-34a levels along the box
plot for the range of distribution between AD and NEC groups. The data are
plotted as inverse Ct derived from qPCR analysis. Student’s t-test was
used to determine statistical significance; ∗∗P < 0.01.
Table 3 | Ranges of 1/deltaCt levels of plasma microRNAs in
Alzheimer disease (AD) patients and normal elderly controls (NEC),
with standard deviation (SD) and median, for miR-34c and miR-34a in
age-matched subcohorts.
Age-matched cohort miR-34c miR-34a
Range (SD) Median Range (SD) Median
AD 0.20–0.53 (0.09) 0.29 0.08–0.28 (0.05) 0.15
NEC 0.05–0.22 (0.05) 0.1 0.06–0.19 (0.03) 0.11
of −0.72, suggesting a strong inverse correlation between the
expression levels of miR-34c and the two cognitive assessment
groups. This inverse correlation between MMSE scores and miR-
34c levels, i.e., lower scores and higher levels, as shown for the
three groups, was not observed for miR-34a expression, with an r
coefficient score of −0.34 (Figure 6B). Likewise, when Pearson’s
correlation was computed for only the moderate and mild clin-
ical groups without NEC, the r-value is very low. These results
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FIGURE 4 | Receiver Operation Characteristic (ROC) curves
representing AD diagnostic tests by miR-34c and miR-34a in
age-matched cohorts. The Receiver Operation Characteristic (ROC) curve
for miR-34c (…..) is an excellent test since the area under the curve is 0.99
(p < 0.0001), number of samples for AD = 25 and NEC = 27. The area
under the Receiver Operation Characteristic (ROC) for miR-34a ( )---- is
0.81 (p = 0.0001) which is a good/fair test, number of samples for AD = 25
and NEC = 27. Sensitivity and specificity are reported based on a cut-off
point chosen using the coordinates of Receiver Operation Characteristic
(ROC) curves with balanced levels of high sensitivity and specificity. The
diagonal line represents a reference line showing zero sensitivity and zero
specificity ( ).
Table 4 | Receiver Operating Characteristic (ROC) curve parameters
for plasma miR-34c and -34a among age-matched subcohorts.
ROC curve miR-34c miR-34a




suggests no relationship between MMSE scores and the levels of
the twomicroRNA expression when comparing themoderate and
mild groups between themselves (Figure 4S).
INCREASED EXPRESSION OF miR-34c IN CELLULAR COMPONENTS OF
AD BLOOD SAMPLES
The observation of increased miR-34c expression in AD plasma
prompted us to determine the level of expression of this
microRNA in the cellular compartment, i.e., PBMCs of age-
matched cohorts of AD and NEC samples. Increased miR-34c
levels were observed in PBMC samples of AD blood specimens,
compared to normal controls (Figure 7A), with a similar increase
for miR-34a in AD over normal controls (Figure 7B). However,
as shown in Table 6, as observed in the plasma samples, there
is scant range overlap for miR-34c levels between AD and age-
matched controls; this is not true for miR-34a levels between the
two groups. Interestingly, the miR-34a levels assayed here as val-
idation for our previous study (Schipper et al., 2007) show the
FIGURE 5 | Differential expression of miR-34c in plasma from patients
with mild and moderate severity of Alzheimer’s disease (AD),
compared with normal elderly controls (NEC) in age-matched cohorts.
AD patients were grouped by mild and moderate severity according to their
Mini-Mental Status Examination (MMSE) scores. (A) Percentile distribution
of samples within the various stages of AD and NEC, plotted against
inverse Ct for individuals of age-matched cohorts. The levels of miR-34c
are higher in samples from moderate (  ) and mild (  ) clinical groups, with
MMSE scores in the range of 10–20 or 21–24, respectively, than NEC (  )
controls in the range of 25–30. (B) Data points added to illustrate the
distribution of individuals within each group of the age-matched cohorts.
We observe NEC to be in a close cluster around the median, whereas AD
patients are scattered in a wider range in both moderate and mild groups.
Both the LSD test (higher type 1 Error) and the Scheffé test (higher
stringency) were used to determine statistical significance. The statistical
significance level for the LSD test is represented with the symbol ( ), and
for Scheffé test is represented with the symbol (∗). P < 0.01,
∗∗P < 0.01.
Table 5 | 1/deltaCt levels of plasma miR-34c and -34a by clinical
category of mild and moderate Alzheimer’s disease (AD) and in
age-matched normal elderly controls (NEC): range with standard
deviation (SD) and median.
miR-34c miR-34a
Range (SD) Median Range (SD) Median
NEC 0.05–0.22 (0.05) 0.1 0.06–0.19 (0.02) 0.1
Mild AD 0.21–0.38 (0.06) 0.26 0.10–0.28 (0.06) 0.16
Moderate AD 0.20–0.53 (0.11) 0.29 0.09–0.21 (0.04) 0.12
same range of fold changes, i.e., ∼3-fold increase in AD samples
beyond normal controls (Figure 5S).
FUNCTIONAL ANALYSIS OF THE REPRESSION OF TARGET PROTEINS
BY OVEREXPRESSING miRs -34a AND -34c IN CULTURED CELLS
We next investigated whether miR-34c represses the same targets
as reported for its sister, miR-34a (He et al., 2007; Yamakuchi
et al., 2008), by transfection studies in cultures of human embry-
onic kidney cells (HEK 293) overexpressing these microRNAs.
Only cultures with >98% of cells showing green fluorescence
positivity for the green fluorescence protein gene (GFP) were
used in our functional assays. Our results with these transfection
experiments show repression of Psen1, Bcl2, Sirt1, and Onecut2
by miR-34a ranging from ∼11% to 27%, with the latter being
the most affected (Figures 8A–C, Table 7). A more pronounced
impact is observed by miR-34c, with repression ranging from
∼16 to 40% (Figures 8A,B,D, Table 7). Co-transfection with
both miRNAs induced further repression of all four target pro-
teins, from ∼32 to 46% (Figures 8A,B,E, Table 7). In all analyses,
repression levels were evaluated by comparing transfected and
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FIGURE 6 | Relationship between expression levels of miR-34c and
miR-34a in plasma with Mini-Mental Status Examination (MMSE)
scores in selected samples of age-matched groups. (A) Plasma
expression levels of miR-34c represented by inverse Ct, plotted against
corresponding MMSE scores. A high Pearson correlation coefficient value
of −0.72 indicates a strong correlation between MMSE scores and
1/deltaCt values, P < 0.0001. (B) Expression levels of miR-34a in plasma of
AD and NEC individuals represented by inverse Ct, plotted against
corresponding MMSE scores. A low Pearson correlation coefficient value of
−0.34 indicates a weak correlation between the MMSE scores and
1/deltaCt values, P = 0.012. Data points of Mini-Mental Status Examination
(MMSE) score are shown as follows: ( ) moderate AD (score 10–20), (  )
mild AD (score 21–24), and ( ) NEC (score 25–30).
FIGURE 7 | Box plot representation of transcript levels of miR-34a and
miR-34c in peripheral blood mononuclear cell (PBMC) samples from
Alzheimer’s disease (AD) patients and normal elderly controls (NEC).
Comparison of levels of miR-34c (A) and miR-34a (B) in AD patients with
that of the NEC cohort in PBMCs, showing increased transcript levels for
both microRNAs in the former group, compared to normal controls.
Student’s t-test was used to determine statistical significance; ∗P < 0.05.
scrambled control cultures, with repression of actin observed at
∼0%. These observations suggest that miR-34c is a stronger sup-
pressor of target gene expression than miR-34a, and that Onecut2
is the most repressed among the target proteins.
DISCUSSION
Members of the microRNA-34 family are present in most tissues,
including PBMC. Our previous study reported miR-34a as a lead
Table 6 | 1/deltaCt level ranges, with standard deviation (SD) and
median, of microRNAs in PBMC from Alzheimer’s disease (AD)
patients and age-matched normal elderly controls (NEC), for miR-34c
and miR-34a.
PBMC miR-34c miR-34a
Range (SD) Median Range (SD) Median
AD 0.07–0.11 (0.01) 0.08 0.13–0.19 (0.01) 0.16
NEC 0.05–0.08 (0.01) 0.07 0.11–0.17 (0.02) 0.14
microRNA from array profiling and validated by qPCR assays,
showing a 2.5-fold increase in PBMC isolated from AD speci-
mens (Schipper et al., 2007). The present study shows that this
microRNA’s sister, miR-34c, is even more prominently increased
in both PBMC and plasma fractions of AD blood samples over
age-matched NEC. Most importantly, the majority of miR-34c
levels among mild AD patients, determined by mini-mental state
examination (MMSE), are elevated beyond those of normal con-
trols. In addition, inclusion of patients with moderate degrees of
AD dementia with mild and normal counterparts in our study
shows a relatively strong inverse relationship between MMSE
scores and levels of this microRNA among the three groups.
Levels of miR-34b, the bicistronic sister of miR-34c, are not sig-
nificantly different between AD and NEC age-matched controls.
Thus, our results reported here will serve as future leads to iden-
tify key microRNA abundance, such as miR-34c, as noninvasive
indicators for plasma changes associated with AD.
Age-matched circulating blood microRNA studies like ours
by design suffer several limitations, such as: (1) restriction of
obtaining gene expression changes at a particular snap-shot time
window; and (2) inability to link with changes of the same gene
expression in individuals’ brains. The first limitation cannot be
addressed by small scale studies like ours, but rather in large con-
sortium studies such as the Alzheimer’s Disease Neuroimaging
Initiative (ADNI) study of the National Institute on Aging, USA,
with longitudinal blood sample collection linking plasma and
CSF analysis study, and MRI imaging of brain changes in the
same individuals. However, most of these studies are centered on
the analysis of protein changes, with some focus on Tau and Aβ
as biomarkers (O’Bryant et al., 2011; Toledo et al., 2011, 2013).
Other studies such as Müller et al. (2014) have limited sample
size because such samples are only available from a very few cen-
ters where longitudinal ante mortem blood or CSF samples are
collected along with follow-up acquisition of autopsy brain spec-
imens. Comparative studies between ante-mortem blood samples
and post mortem autopsy will emerge in future studies, yielding
results elucidating the relationships between plasma biomarkers
and brain pathology structural changes, including but not limited
to amyloid plaques and Tau-associated tangle formation.
To identify body fluid-associated microRNA biomarkers for
neurodegeneration, standardization of the sample collection pro-
tocol and quality control of RNA isolation are two obvious quality
control criteria in any study of this kind. Although we have
established meticulous procedures for collecting blood samples
and further processing to PBMC and plasma fractions, a signif-
icant portion, ∼20%, of the RNA fractions isolated from these
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FIGURE 8 | Repression of expression of selected candidate target genes
of miR-34a and miR-34c by transfection analysis. Human embryonic
kidney (HEK 293) cultures were transfected with green fluorescence protein
(GFP) expression vectors containing sequences encoding miR-34a, miR-34c,
or a scrambled sequence. Controls included un-infected cultures, mock
transfected cultures, cells transfected with either GFP vector alone or
carrying a computer-generated scrambled sequence. (A) Western blot
analysis of cell lysates probed for SIRT1, Onecut2, Presenilin-1, Bcl2, and
β-actin proteins; (B) Graphic representation of a comparison of band
intensities between the various treatments; image intensities of Western
blotted bands were normalized against the β-actin band, which is constant
throughout. Graphic representation showing percent of repression,
estimated using scrambled controls for comparison (panels C–E): transfection
with miR-34a (C); miR-34c (D); miR-34a and miR-34c (E). One-way ANOVA
followed by LSD test was used to determine statistical significance;
∗P < 0.05, ∗∗P < 0.01.
Table 7 | Levels of miR-34a and miR-34c repression of four target
genes’ expression.
miR-34a miR-34c miR-34a + 34c
vs. scrambled vs. scrambled vs. scrambled
Protein Mean Mean Mean
% repression (SD) % repression (SD) % repression (SD)
Onecut2 27.15 (3.34) 40.13 (2.85) 46.42 (0.63)
SIRT1 22.28 (7.68) 26.09 (6.78) 34.89 (5.92)
Bcl2 23.27 (2.87) 16.06 (2.48) 32.57 (1.85)
Psen1 10.69 (4.8) 18.89 (5.94) 25.54 (6.39)
β-actin 0 0 0
Percent repression of target proteins in HEK 293 cells transfected with miR-
34a, miR-34c, or both miRNAs. The repression levels shown here represent
protein band intensities, after normalization against β-actin band intensities,
when cultures transfected by microRNA are compared with those transfected
by scrambled controls. As shown in Figure 8, the % change of β-actin levels
between cultures transfected by the microRNAs of interest and by the scram-
bled controls is ∼0. Mean % repression with standard deviation (SD) of each
miR for each protein is tabulated.
samples were unacceptable because of poor RNA integrity. Even
among the 70–80 samples with good RNA quality, we had to
narrow our study to 25 AD and 27 NEC as shown in Table 1, in
order to satisfy age-matched criteria for our study. With samples
from these two subcohorts, as in most neurodegenerative stud-
ies, before proceeding to qPCR assays of a particular microRNA
of interest, we implemented quality control to insure the cDNA
synthesis part of the assays by incorporating Cel 39 spike-in in the
step of RNA isolation.
Besides the above issues, selection of reference microRNAs for
determination of microRNA levels of expression is crucial for
studies of blood samples of neuronal disorders. We use miR-16
as our reference microRNA, following the report by Gaughwin
et al. (2011), who used it as the reference microRNA to show that
miR-34b is elevated in the plasma of Huntingdon mutation gene
carriers, prior to disease manifestation. Interestingly, our study
with this microRNA shows that miR-34b levels do not differ sig-
nificantly in plasma specimens between AD patients and NEC. A
recent study by Müller et al. (2014) shows that miR-16 and miR-
146 are increased in AD in both hippocampus and cerebrospinal
fluid (CSF). However, this report also suggests that miR-16, a
major red blood cell microRNA (Kirschner et al., 2011, 2013;
McDonald et al., 2011), may be contaminatedby hemolysis in
CSF samples; even as little as 100μl of erythrocytes added skews
the qPCR results (Müller et al., 2014). In addition, several other
microRNAs reported so far as unchanged in AD tissue have been
used as references to determine levels of microRNAs of interest
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(Geekiyanage et al., 2012; Sheinerman et al., 2012; Sheinerman
and Umansky, 2013). Notwithstanding all these reports, no uni-
fying approach of selecting appropriate reference controls has yet
been reached. At present we are limited to the use of miR-16 as
the reference, based on the rationale that we found no significant
variance in it among our samples, as shown in Figures 1E,F.
The widespread variance in levels of both miR-34c and its
sister, miR-34a in AD plasma compared with the tight NEC
cluster range, shown in Figures 1–4, clearly suggests individual
variability in the control of these microRNAs’ expression. From
our small age-matched cohorts, miR-34c levels may be a bet-
ter candidate than miR-34a and miR-34b for future large-scale
study as a blood-based biomarker, simply because its expression
in most mild AD patients shows higher levels than most NEC.
The ROC analyses performed for both miR-34c and miR-34a
1/deltaCt values in age-matched cohorts proved the former to be
an excellent discriminant (AUC = 0.99), whereas the latter was
merely fairly good (AUC = 0.81). However, these results suggest
the need of further research with larger cohorts, to stringently
validate our results of sensitivity using miR-34c as a diagnostic
biomarker for plasma samples. Likewise, the inverse correlation,
observed only when the moderate and mild groups are com-
pared with their NEC between cognitive scoring and levels of
expression of miR-34c in plasma also needs future studies with
larger cohorts to define their true relationship. Nevertheless, our
findings open the possibility that plasma microRNAs, along with
other biomarkers, may be fertile ground for future research link-
ing cognitive decline with changes of gene expression in blood
samples.
The increased miR-34c in AD plasma may derive from PBMC,
where miR-34c is also increased. As reported, microRNAs present
in the circulating plasma may be found either in the encapsulated
vesicles known as exosomes, or in lipid- or protein-associated free
particulates (Smalheiser, 2007; Etheridge et al., 2011). Reports so
far are inconclusive as to what proportion of plasma microRNAs
are associated with the former vs. the latter components. Future
comparative studies of PBMC, exosomal and free-form miR-34c
will reveal the relationship among these three components of
AD circulating blood specimens responsible for this microRNA’s
increased expression.
MicroRNA-34c, as reported for its sister, miR-34a (He et al.,
2007; Yamakuchi et al., 2008) and as shown in Figure 8, represses
Bcl2, SIRT1, Psen1, and Onecut2, all associated with cellular
survival and oxidative defense signaling (Clotman et al., 2005;
Goodall et al., 2013). This led us to suggest that increasedmiR-34c
may be one of many factors contributing to an overall systemic
weakening of stress defense and cell survival, as suggested in our
model presented in Figure 9. Life-long cumulative oxidative stress
induction of p53 up-regulation may activate the expression of
this microRNA, with a steadily increasing trend during aging
(Li et al., 2011b,c). In AD, this oxidative stress may be further
enhanced, manifested in brain as well as perhaps system-wide,
reflected in circulating blood by both PBMC and plasma (Maes
et al., 2010; Goodall et al., 2013). Future culture experiments
in PBMC isolated from AD patients compared with those from
normal counterparts will allow us to investigate whether these
cells with increased miR-34c levels are indeed prone to apoptotic
FIGURE 9 | A model suggesting that increased circulating miR-34c
expression represses targets involved in oxidative stress and cell
survival signaling pathways.
death, and whether plasma from the same samples stimulates
stress and apoptotic signaling in neighboring cells.
In conclusion, data presented here indicate that levels of miR-
34c significantly increase in plasma samples of sporadic AD.
Future studies with larger age-matched cohorts will validate these
results, and reveal whether this microRNA change is characteristic
of sporadic AD as a biomarker criterion, and further compar-
ative studies will elucidate whether it is a common biomarker
shared among various neurodegenerative disorders, associated
with the decline of oxidative defense and cell survival in neuronal
dysfunction.
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